Description of Medical ServiceTisagenlecleucel is an autologous, murine anti-CD19 Chimeric Antigen Receptor T cell therapeutic process, involving harvesting, modifying, expanding and re-infusing a patient's own immune T-cells, to target and destroy certain cancerous cells.
Description of Medical ConditionDiffuse Large B-Cell Lymphoma is an aggressive and common subtype of Non-Hodgkin Lymphoma.
Reason for ApplicationRequest to amend the eligibility criteria to remove the requirement for patients to be “CD19-positive”.
Medical Service TypeHybrid health technology
Previous Application Number/s1519
Public Summary DocumentPublic Summary Document (PDF 318 KB)
Public Summary Document (Word 73 KB)